Welcome to our dedicated page for Briacell Therapeutics news (Ticker: BCTX), a resource for investors and traders seeking the latest updates and insights on Briacell Therapeutics stock.
BriaCell Therapeutics Corp. (BCTX) generates frequent news flow as a clinical-stage biotechnology company developing novel immunotherapies for cancer, with a strong focus on metastatic breast cancer. News about BriaCell often centers on clinical trial milestones, emerging efficacy and safety data, biomarker analyses, and platform advancements across its Bria-IMT™, Bria-OTS™, and Bria-OTS+™ programs.
Investors and researchers following BCTX news can track updates on the pivotal Phase 3 Bria-IMT trial in advanced metastatic breast cancer, including enrollment progress, interim analyses, and presentations at major scientific meetings such as the San Antonio Breast Cancer Symposium (SABCS®). Company releases describe survival outcomes, progression-free survival signals, and potential predictive biomarkers like neutrophil-to-lymphocyte ratio, delayed-type hypersensitivity responses, and Th1-biased cytokine signatures.
BriaCell’s news stream also highlights developments in its Bria-OTS and Bria-OTS+ off-the-shelf immunotherapy platforms. Announcements include clinical observations such as sustained complete resolution of lung metastasis in a metastatic breast cancer patient treated with Bria-OTS, as well as preclinical data showing robust innate and adaptive immune activation by Bria-OTS+ candidates Bria-BRES+™ and Bria-PROS+™ in breast and prostate cancer models.
Additional coverage includes corporate and pipeline updates from BriaPro Therapeutics Corp., BriaCell’s subsidiary, and its AI-driven collaboration with Receptor.AI to design isoform-selective kinase inhibitors. For those monitoring BCTX, this news page provides a centralized view of regulatory designations, trial recognitions in scientific publications, collaborative research announcements, and detailed scientific poster summaries. Regular visits can help readers follow how BriaCell’s immunotherapy platforms evolve from preclinical research through late-stage clinical evaluation.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) has secured a new US patent for its personalized off-the-shelf cancer immunotherapy technology, extending protection until May 2040. The company plans to commence its Bria-OTS™ clinical study in the first half of 2023, as guided by the FDA. Additionally, two new clinical sites, Carle Cancer Institute in Illinois and American Oncology Network in Maryland, have been added for the Phase II Bria-IMT™ study, aimed at improving treatment access for advanced breast cancer patients.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) presented promising clinical data at the 2022 San Antonio Breast Cancer Symposium for its Bria-IMT™ combination regimen targeting advanced metastatic breast cancer patients. Positive outcomes included tumor shrinkage, disease control, and improved progression-free survival. Patients reported better quality of life and less pain. The treatment demonstrated excellent tolerability, with no dose-limiting toxicities. Future studies aim to validate these findings further and explore the potential of the Bria-OTS2.0 personalized immunotherapy.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) has announced a collaboration with BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW), focusing on AI-driven antibody discovery for cancer therapies. BioStrand, a subsidiary of IPA, will utilize its LENSai™ software to create clinical molecules. The partnership includes an upfront payment of US$500,000 for BioStrand, along with additional success-based milestones. This initiative aims to enhance the efficiency of developing targeted treatments, aligning with the long-term vision of advancing precision medicine.
BriaCell Therapeutics Corp. (BCTX, BCTXW) announced promising initial efficacy results from its phase I/IIaa clinical trial of Bria-IMT™ combined with Incyte’s retifanlimab for advanced breast cancer. Presenting at the SITC annual meeting, they reported a 70% disease control rate and tumor shrinkage in 70% of 12 patients, all of whom had previously failed multiple therapies. The company is in talks with the FDA to progress to pivotal studies, aiming for broader patient access to this innovative treatment.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) has announced promising results from a Phase I/IIa study involving 12 advanced breast cancer patients treated with Bria-IMT™ and Incyte's retifanlimab. The study showed that 70% of patients achieved either disease control or progression-free survival, with a disease control rate of 57%. These results are significant as the patients had previously undergone at least two unsuccessful therapies. The regimen was well tolerated, and BriaCell has received FDA fast track designation for the study.
BriaCell Therapeutics has completed the Phase I trial of Bria-IMT™ combined with Incyte’s retifanlimab for advanced breast cancer, showing a favorable safety profile among 12 patients. The trial participants had failed at least two prior therapies. The FDA has granted the program a fast track designation, and the Phase II efficacy study is now underway, focusing on survival data and clinical benefits. A randomized controlled design will compare treatment regimens with different dosing schedules. BriaCell plans to meet with the FDA later this year to discuss the next steps.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) has announced the addition of Mayo Clinic in Jacksonville, Florida, as a clinical site for its Phase I/II study of Bria-IMT™ combined with Incyte's PD-1 inhibitor, retifanlimab, aimed at treating advanced breast cancer. The study is part of BriaCell's mission to leverage innovative immunotherapy approaches to improve patient outcomes. Dr. Giuseppe Del Priore, the Chief Medical Officer, expressed optimism about the collaboration and the potential for advancements in cancer treatment.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) has announced that its lead product candidate, Bria-IMT™, will be featured in three poster presentations at the 2022 San Antonio Breast Cancer Symposium from December 6-10. The presentations aim to share clinical findings with healthcare professionals treating advanced breast cancer patients who are unresponsive to existing therapies. The posters will be displayed at the Henry B. Gonzalez Convention Center in San Antonio, Texas. Copies will be available online after the event.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) has partnered with Caris Life Sciences to enhance its capabilities in patient identification for clinical trials. The collaboration aims to expedite enrollment in a Phase I/II trial focused on advanced metastatic breast cancer. Caris will utilize its extensive oncology network and molecular profiling technologies to assist BriaCell in targeting patients most likely to benefit from its immunotherapy treatments. This partnership is expected to leverage Caris' advanced biomarker technology to improve patient outcomes.
BriaCell Therapeutics Corp. (BCTX, BCTXW) will present new data on its immunotherapy, Bria-IMT™, at the SITC 37th Annual Meeting from November 10-12, 2022, in Boston, MA. The presentation highlights clinical benefits observed in advanced breast cancer patients, showcasing extended survival and tumor reductions in those matching specific HLA types. The session aims to further optimize off-the-shelf personalized immunotherapies. The poster presentation will be available online afterwards, offering insights into BriaCell's innovative approaches to cancer treatment.